Rigel Pharma (NASDAQ: RIGL) reported Q1 EPS of ($0.05), $0.02 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $29.53 million versus the consensus estimate of $31.48 million.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.